Medical Care
Global CGRP Inhibitor Market Research Report 2025
- May 12, 25
- ID: 233394
- Pages: 81
- Figures: 83
- Views: 28
The global market for CGRP Inhibitor was valued at US$ 3157 million in the year 2024 and is projected to reach a revised size of US$ 4593 million by 2031, growing at a CAGR of 5.6% during the forecast period.
CGRP inhibitors are a class of medications that block the activity of calcitonin gene-related peptide (CGRP), a neuropeptide involved in the pathophysiology of migraines. By targeting either the CGRP ligand or its receptor, these drugs prevent the dilation of blood vessels and inflammation associated with migraine attacks. CGRP inhibitors are used primarily for the prevention and acute treatment of migraines and include monoclonal antibodies (e.g., erenumab, fremanezumab, galcanezumab) and small molecule receptor antagonists (gepants). They are generally well tolerated and represent a significant advancement in migraine therapy.
North American market for CGRP Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for CGRP Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for CGRP Inhibitor in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of CGRP Inhibitor include AbbVie, Amgen, Eli Lilly, Teva Pharmaceutical, Pfizer, Lundbeck, Novartis, Bristol Myers Squibb, Satsuma, Zosano Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CGRP Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CGRP Inhibitor.
The CGRP Inhibitor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CGRP Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CGRP Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Amgen
Eli Lilly
Teva Pharmaceutical
Pfizer
Lundbeck
Novartis
Bristol Myers Squibb
Satsuma
Zosano Pharma
Dr.Reddy’s Laboratories
Segment by Type
Infusions
Oral
Other
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CGRP Inhibitor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
CGRP inhibitors are a class of medications that block the activity of calcitonin gene-related peptide (CGRP), a neuropeptide involved in the pathophysiology of migraines. By targeting either the CGRP ligand or its receptor, these drugs prevent the dilation of blood vessels and inflammation associated with migraine attacks. CGRP inhibitors are used primarily for the prevention and acute treatment of migraines and include monoclonal antibodies (e.g., erenumab, fremanezumab, galcanezumab) and small molecule receptor antagonists (gepants). They are generally well tolerated and represent a significant advancement in migraine therapy.
North American market for CGRP Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for CGRP Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for CGRP Inhibitor in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of CGRP Inhibitor include AbbVie, Amgen, Eli Lilly, Teva Pharmaceutical, Pfizer, Lundbeck, Novartis, Bristol Myers Squibb, Satsuma, Zosano Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CGRP Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CGRP Inhibitor.
The CGRP Inhibitor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CGRP Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CGRP Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Amgen
Eli Lilly
Teva Pharmaceutical
Pfizer
Lundbeck
Novartis
Bristol Myers Squibb
Satsuma
Zosano Pharma
Dr.Reddy’s Laboratories
Segment by Type
Infusions
Oral
Other
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CGRP Inhibitor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CGRP Inhibitor Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Infusions
1.2.3 Oral
1.2.4 Other
1.3 Market by Application
1.3.1 Global CGRP Inhibitor Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global CGRP Inhibitor Market Perspective (2020-2031)
2.2 Global CGRP Inhibitor Growth Trends by Region
2.2.1 Global CGRP Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 CGRP Inhibitor Historic Market Size by Region (2020-2025)
2.2.3 CGRP Inhibitor Forecasted Market Size by Region (2026-2031)
2.3 CGRP Inhibitor Market Dynamics
2.3.1 CGRP Inhibitor Industry Trends
2.3.2 CGRP Inhibitor Market Drivers
2.3.3 CGRP Inhibitor Market Challenges
2.3.4 CGRP Inhibitor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CGRP Inhibitor Players by Revenue
3.1.1 Global Top CGRP Inhibitor Players by Revenue (2020-2025)
3.1.2 Global CGRP Inhibitor Revenue Market Share by Players (2020-2025)
3.2 Global Top CGRP Inhibitor Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by CGRP Inhibitor Revenue
3.4 Global CGRP Inhibitor Market Concentration Ratio
3.4.1 Global CGRP Inhibitor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CGRP Inhibitor Revenue in 2024
3.5 Global Key Players of CGRP Inhibitor Head office and Area Served
3.6 Global Key Players of CGRP Inhibitor, Product and Application
3.7 Global Key Players of CGRP Inhibitor, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 CGRP Inhibitor Breakdown Data by Type
4.1 Global CGRP Inhibitor Historic Market Size by Type (2020-2025)
4.2 Global CGRP Inhibitor Forecasted Market Size by Type (2026-2031)
5 CGRP Inhibitor Breakdown Data by Application
5.1 Global CGRP Inhibitor Historic Market Size by Application (2020-2025)
5.2 Global CGRP Inhibitor Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America CGRP Inhibitor Market Size (2020-2031)
6.2 North America CGRP Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America CGRP Inhibitor Market Size by Country (2020-2025)
6.4 North America CGRP Inhibitor Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CGRP Inhibitor Market Size (2020-2031)
7.2 Europe CGRP Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe CGRP Inhibitor Market Size by Country (2020-2025)
7.4 Europe CGRP Inhibitor Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CGRP Inhibitor Market Size (2020-2031)
8.2 Asia-Pacific CGRP Inhibitor Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific CGRP Inhibitor Market Size by Region (2020-2025)
8.4 Asia-Pacific CGRP Inhibitor Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CGRP Inhibitor Market Size (2020-2031)
9.2 Latin America CGRP Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America CGRP Inhibitor Market Size by Country (2020-2025)
9.4 Latin America CGRP Inhibitor Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CGRP Inhibitor Market Size (2020-2031)
10.2 Middle East & Africa CGRP Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa CGRP Inhibitor Market Size by Country (2020-2025)
10.4 Middle East & Africa CGRP Inhibitor Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie CGRP Inhibitor Introduction
11.1.4 AbbVie Revenue in CGRP Inhibitor Business (2020-2025)
11.1.5 AbbVie Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen CGRP Inhibitor Introduction
11.2.4 Amgen Revenue in CGRP Inhibitor Business (2020-2025)
11.2.5 Amgen Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly CGRP Inhibitor Introduction
11.3.4 Eli Lilly Revenue in CGRP Inhibitor Business (2020-2025)
11.3.5 Eli Lilly Recent Development
11.4 Teva Pharmaceutical
11.4.1 Teva Pharmaceutical Company Details
11.4.2 Teva Pharmaceutical Business Overview
11.4.3 Teva Pharmaceutical CGRP Inhibitor Introduction
11.4.4 Teva Pharmaceutical Revenue in CGRP Inhibitor Business (2020-2025)
11.4.5 Teva Pharmaceutical Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer CGRP Inhibitor Introduction
11.5.4 Pfizer Revenue in CGRP Inhibitor Business (2020-2025)
11.5.5 Pfizer Recent Development
11.6 Lundbeck
11.6.1 Lundbeck Company Details
11.6.2 Lundbeck Business Overview
11.6.3 Lundbeck CGRP Inhibitor Introduction
11.6.4 Lundbeck Revenue in CGRP Inhibitor Business (2020-2025)
11.6.5 Lundbeck Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis CGRP Inhibitor Introduction
11.7.4 Novartis Revenue in CGRP Inhibitor Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 Bristol Myers Squibb
11.8.1 Bristol Myers Squibb Company Details
11.8.2 Bristol Myers Squibb Business Overview
11.8.3 Bristol Myers Squibb CGRP Inhibitor Introduction
11.8.4 Bristol Myers Squibb Revenue in CGRP Inhibitor Business (2020-2025)
11.8.5 Bristol Myers Squibb Recent Development
11.9 Satsuma
11.9.1 Satsuma Company Details
11.9.2 Satsuma Business Overview
11.9.3 Satsuma CGRP Inhibitor Introduction
11.9.4 Satsuma Revenue in CGRP Inhibitor Business (2020-2025)
11.9.5 Satsuma Recent Development
11.10 Zosano Pharma
11.10.1 Zosano Pharma Company Details
11.10.2 Zosano Pharma Business Overview
11.10.3 Zosano Pharma CGRP Inhibitor Introduction
11.10.4 Zosano Pharma Revenue in CGRP Inhibitor Business (2020-2025)
11.10.5 Zosano Pharma Recent Development
11.11 Dr.Reddy’s Laboratories
11.11.1 Dr.Reddy’s Laboratories Company Details
11.11.2 Dr.Reddy’s Laboratories Business Overview
11.11.3 Dr.Reddy’s Laboratories CGRP Inhibitor Introduction
11.11.4 Dr.Reddy’s Laboratories Revenue in CGRP Inhibitor Business (2020-2025)
11.11.5 Dr.Reddy’s Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CGRP Inhibitor Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Infusions
1.2.3 Oral
1.2.4 Other
1.3 Market by Application
1.3.1 Global CGRP Inhibitor Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global CGRP Inhibitor Market Perspective (2020-2031)
2.2 Global CGRP Inhibitor Growth Trends by Region
2.2.1 Global CGRP Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 CGRP Inhibitor Historic Market Size by Region (2020-2025)
2.2.3 CGRP Inhibitor Forecasted Market Size by Region (2026-2031)
2.3 CGRP Inhibitor Market Dynamics
2.3.1 CGRP Inhibitor Industry Trends
2.3.2 CGRP Inhibitor Market Drivers
2.3.3 CGRP Inhibitor Market Challenges
2.3.4 CGRP Inhibitor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CGRP Inhibitor Players by Revenue
3.1.1 Global Top CGRP Inhibitor Players by Revenue (2020-2025)
3.1.2 Global CGRP Inhibitor Revenue Market Share by Players (2020-2025)
3.2 Global Top CGRP Inhibitor Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by CGRP Inhibitor Revenue
3.4 Global CGRP Inhibitor Market Concentration Ratio
3.4.1 Global CGRP Inhibitor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CGRP Inhibitor Revenue in 2024
3.5 Global Key Players of CGRP Inhibitor Head office and Area Served
3.6 Global Key Players of CGRP Inhibitor, Product and Application
3.7 Global Key Players of CGRP Inhibitor, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 CGRP Inhibitor Breakdown Data by Type
4.1 Global CGRP Inhibitor Historic Market Size by Type (2020-2025)
4.2 Global CGRP Inhibitor Forecasted Market Size by Type (2026-2031)
5 CGRP Inhibitor Breakdown Data by Application
5.1 Global CGRP Inhibitor Historic Market Size by Application (2020-2025)
5.2 Global CGRP Inhibitor Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America CGRP Inhibitor Market Size (2020-2031)
6.2 North America CGRP Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America CGRP Inhibitor Market Size by Country (2020-2025)
6.4 North America CGRP Inhibitor Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CGRP Inhibitor Market Size (2020-2031)
7.2 Europe CGRP Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe CGRP Inhibitor Market Size by Country (2020-2025)
7.4 Europe CGRP Inhibitor Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CGRP Inhibitor Market Size (2020-2031)
8.2 Asia-Pacific CGRP Inhibitor Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific CGRP Inhibitor Market Size by Region (2020-2025)
8.4 Asia-Pacific CGRP Inhibitor Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CGRP Inhibitor Market Size (2020-2031)
9.2 Latin America CGRP Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America CGRP Inhibitor Market Size by Country (2020-2025)
9.4 Latin America CGRP Inhibitor Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CGRP Inhibitor Market Size (2020-2031)
10.2 Middle East & Africa CGRP Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa CGRP Inhibitor Market Size by Country (2020-2025)
10.4 Middle East & Africa CGRP Inhibitor Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie CGRP Inhibitor Introduction
11.1.4 AbbVie Revenue in CGRP Inhibitor Business (2020-2025)
11.1.5 AbbVie Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen CGRP Inhibitor Introduction
11.2.4 Amgen Revenue in CGRP Inhibitor Business (2020-2025)
11.2.5 Amgen Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly CGRP Inhibitor Introduction
11.3.4 Eli Lilly Revenue in CGRP Inhibitor Business (2020-2025)
11.3.5 Eli Lilly Recent Development
11.4 Teva Pharmaceutical
11.4.1 Teva Pharmaceutical Company Details
11.4.2 Teva Pharmaceutical Business Overview
11.4.3 Teva Pharmaceutical CGRP Inhibitor Introduction
11.4.4 Teva Pharmaceutical Revenue in CGRP Inhibitor Business (2020-2025)
11.4.5 Teva Pharmaceutical Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer CGRP Inhibitor Introduction
11.5.4 Pfizer Revenue in CGRP Inhibitor Business (2020-2025)
11.5.5 Pfizer Recent Development
11.6 Lundbeck
11.6.1 Lundbeck Company Details
11.6.2 Lundbeck Business Overview
11.6.3 Lundbeck CGRP Inhibitor Introduction
11.6.4 Lundbeck Revenue in CGRP Inhibitor Business (2020-2025)
11.6.5 Lundbeck Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis CGRP Inhibitor Introduction
11.7.4 Novartis Revenue in CGRP Inhibitor Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 Bristol Myers Squibb
11.8.1 Bristol Myers Squibb Company Details
11.8.2 Bristol Myers Squibb Business Overview
11.8.3 Bristol Myers Squibb CGRP Inhibitor Introduction
11.8.4 Bristol Myers Squibb Revenue in CGRP Inhibitor Business (2020-2025)
11.8.5 Bristol Myers Squibb Recent Development
11.9 Satsuma
11.9.1 Satsuma Company Details
11.9.2 Satsuma Business Overview
11.9.3 Satsuma CGRP Inhibitor Introduction
11.9.4 Satsuma Revenue in CGRP Inhibitor Business (2020-2025)
11.9.5 Satsuma Recent Development
11.10 Zosano Pharma
11.10.1 Zosano Pharma Company Details
11.10.2 Zosano Pharma Business Overview
11.10.3 Zosano Pharma CGRP Inhibitor Introduction
11.10.4 Zosano Pharma Revenue in CGRP Inhibitor Business (2020-2025)
11.10.5 Zosano Pharma Recent Development
11.11 Dr.Reddy’s Laboratories
11.11.1 Dr.Reddy’s Laboratories Company Details
11.11.2 Dr.Reddy’s Laboratories Business Overview
11.11.3 Dr.Reddy’s Laboratories CGRP Inhibitor Introduction
11.11.4 Dr.Reddy’s Laboratories Revenue in CGRP Inhibitor Business (2020-2025)
11.11.5 Dr.Reddy’s Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global CGRP Inhibitor Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Infusions
Table 3. Key Players of Oral
Table 4. Key Players of Other
Table 5. Global CGRP Inhibitor Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global CGRP Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global CGRP Inhibitor Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global CGRP Inhibitor Market Share by Region (2020-2025)
Table 9. Global CGRP Inhibitor Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global CGRP Inhibitor Market Share by Region (2026-2031)
Table 11. CGRP Inhibitor Market Trends
Table 12. CGRP Inhibitor Market Drivers
Table 13. CGRP Inhibitor Market Challenges
Table 14. CGRP Inhibitor Market Restraints
Table 15. Global CGRP Inhibitor Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global CGRP Inhibitor Market Share by Players (2020-2025)
Table 17. Global Top CGRP Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CGRP Inhibitor as of 2024)
Table 18. Ranking of Global Top CGRP Inhibitor Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by CGRP Inhibitor Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of CGRP Inhibitor, Headquarters and Area Served
Table 21. Global Key Players of CGRP Inhibitor, Product and Application
Table 22. Global Key Players of CGRP Inhibitor, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global CGRP Inhibitor Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global CGRP Inhibitor Revenue Market Share by Type (2020-2025)
Table 26. Global CGRP Inhibitor Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global CGRP Inhibitor Revenue Market Share by Type (2026-2031)
Table 28. Global CGRP Inhibitor Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global CGRP Inhibitor Revenue Market Share by Application (2020-2025)
Table 30. Global CGRP Inhibitor Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global CGRP Inhibitor Revenue Market Share by Application (2026-2031)
Table 32. North America CGRP Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America CGRP Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America CGRP Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe CGRP Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe CGRP Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe CGRP Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific CGRP Inhibitor Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific CGRP Inhibitor Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific CGRP Inhibitor Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America CGRP Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America CGRP Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America CGRP Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa CGRP Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa CGRP Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa CGRP Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 47. AbbVie Company Details
Table 48. AbbVie Business Overview
Table 49. AbbVie CGRP Inhibitor Product
Table 50. AbbVie Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 51. AbbVie Recent Development
Table 52. Amgen Company Details
Table 53. Amgen Business Overview
Table 54. Amgen CGRP Inhibitor Product
Table 55. Amgen Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 56. Amgen Recent Development
Table 57. Eli Lilly Company Details
Table 58. Eli Lilly Business Overview
Table 59. Eli Lilly CGRP Inhibitor Product
Table 60. Eli Lilly Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 61. Eli Lilly Recent Development
Table 62. Teva Pharmaceutical Company Details
Table 63. Teva Pharmaceutical Business Overview
Table 64. Teva Pharmaceutical CGRP Inhibitor Product
Table 65. Teva Pharmaceutical Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 66. Teva Pharmaceutical Recent Development
Table 67. Pfizer Company Details
Table 68. Pfizer Business Overview
Table 69. Pfizer CGRP Inhibitor Product
Table 70. Pfizer Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Lundbeck Company Details
Table 73. Lundbeck Business Overview
Table 74. Lundbeck CGRP Inhibitor Product
Table 75. Lundbeck Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 76. Lundbeck Recent Development
Table 77. Novartis Company Details
Table 78. Novartis Business Overview
Table 79. Novartis CGRP Inhibitor Product
Table 80. Novartis Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 81. Novartis Recent Development
Table 82. Bristol Myers Squibb Company Details
Table 83. Bristol Myers Squibb Business Overview
Table 84. Bristol Myers Squibb CGRP Inhibitor Product
Table 85. Bristol Myers Squibb Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 86. Bristol Myers Squibb Recent Development
Table 87. Satsuma Company Details
Table 88. Satsuma Business Overview
Table 89. Satsuma CGRP Inhibitor Product
Table 90. Satsuma Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 91. Satsuma Recent Development
Table 92. Zosano Pharma Company Details
Table 93. Zosano Pharma Business Overview
Table 94. Zosano Pharma CGRP Inhibitor Product
Table 95. Zosano Pharma Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 96. Zosano Pharma Recent Development
Table 97. Dr.Reddy’s Laboratories Company Details
Table 98. Dr.Reddy’s Laboratories Business Overview
Table 99. Dr.Reddy’s Laboratories CGRP Inhibitor Product
Table 100. Dr.Reddy’s Laboratories Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 101. Dr.Reddy’s Laboratories Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
Table 105. Authors List of This Report
List of Figures
Figure 1. CGRP Inhibitor Picture
Figure 2. Global CGRP Inhibitor Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global CGRP Inhibitor Market Share by Type: 2024 VS 2031
Figure 4. Infusions Features
Figure 5. Oral Features
Figure 6. Other Features
Figure 7. Global CGRP Inhibitor Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global CGRP Inhibitor Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Others Case Studies
Figure 12. CGRP Inhibitor Report Years Considered
Figure 13. Global CGRP Inhibitor Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global CGRP Inhibitor Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global CGRP Inhibitor Market Share by Region: 2024 VS 2031
Figure 16. Global CGRP Inhibitor Market Share by Players in 2024
Figure 17. Global CGRP Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by CGRP Inhibitor Revenue in 2024
Figure 19. North America CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America CGRP Inhibitor Market Share by Country (2020-2031)
Figure 21. United States CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe CGRP Inhibitor Market Share by Country (2020-2031)
Figure 25. Germany CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific CGRP Inhibitor Market Share by Region (2020-2031)
Figure 33. China CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America CGRP Inhibitor Market Share by Country (2020-2031)
Figure 41. Mexico CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa CGRP Inhibitor Market Share by Country (2020-2031)
Figure 45. Turkey CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. AbbVie Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 49. Amgen Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 50. Eli Lilly Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 51. Teva Pharmaceutical Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 52. Pfizer Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 53. Lundbeck Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 54. Novartis Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 55. Bristol Myers Squibb Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 56. Satsuma Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 57. Zosano Pharma Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 58. Dr.Reddy’s Laboratories Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Table 1. Global CGRP Inhibitor Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Infusions
Table 3. Key Players of Oral
Table 4. Key Players of Other
Table 5. Global CGRP Inhibitor Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global CGRP Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global CGRP Inhibitor Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global CGRP Inhibitor Market Share by Region (2020-2025)
Table 9. Global CGRP Inhibitor Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global CGRP Inhibitor Market Share by Region (2026-2031)
Table 11. CGRP Inhibitor Market Trends
Table 12. CGRP Inhibitor Market Drivers
Table 13. CGRP Inhibitor Market Challenges
Table 14. CGRP Inhibitor Market Restraints
Table 15. Global CGRP Inhibitor Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global CGRP Inhibitor Market Share by Players (2020-2025)
Table 17. Global Top CGRP Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CGRP Inhibitor as of 2024)
Table 18. Ranking of Global Top CGRP Inhibitor Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by CGRP Inhibitor Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of CGRP Inhibitor, Headquarters and Area Served
Table 21. Global Key Players of CGRP Inhibitor, Product and Application
Table 22. Global Key Players of CGRP Inhibitor, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global CGRP Inhibitor Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global CGRP Inhibitor Revenue Market Share by Type (2020-2025)
Table 26. Global CGRP Inhibitor Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global CGRP Inhibitor Revenue Market Share by Type (2026-2031)
Table 28. Global CGRP Inhibitor Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global CGRP Inhibitor Revenue Market Share by Application (2020-2025)
Table 30. Global CGRP Inhibitor Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global CGRP Inhibitor Revenue Market Share by Application (2026-2031)
Table 32. North America CGRP Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America CGRP Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America CGRP Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe CGRP Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe CGRP Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe CGRP Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific CGRP Inhibitor Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific CGRP Inhibitor Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific CGRP Inhibitor Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America CGRP Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America CGRP Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America CGRP Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa CGRP Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa CGRP Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa CGRP Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 47. AbbVie Company Details
Table 48. AbbVie Business Overview
Table 49. AbbVie CGRP Inhibitor Product
Table 50. AbbVie Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 51. AbbVie Recent Development
Table 52. Amgen Company Details
Table 53. Amgen Business Overview
Table 54. Amgen CGRP Inhibitor Product
Table 55. Amgen Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 56. Amgen Recent Development
Table 57. Eli Lilly Company Details
Table 58. Eli Lilly Business Overview
Table 59. Eli Lilly CGRP Inhibitor Product
Table 60. Eli Lilly Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 61. Eli Lilly Recent Development
Table 62. Teva Pharmaceutical Company Details
Table 63. Teva Pharmaceutical Business Overview
Table 64. Teva Pharmaceutical CGRP Inhibitor Product
Table 65. Teva Pharmaceutical Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 66. Teva Pharmaceutical Recent Development
Table 67. Pfizer Company Details
Table 68. Pfizer Business Overview
Table 69. Pfizer CGRP Inhibitor Product
Table 70. Pfizer Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Lundbeck Company Details
Table 73. Lundbeck Business Overview
Table 74. Lundbeck CGRP Inhibitor Product
Table 75. Lundbeck Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 76. Lundbeck Recent Development
Table 77. Novartis Company Details
Table 78. Novartis Business Overview
Table 79. Novartis CGRP Inhibitor Product
Table 80. Novartis Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 81. Novartis Recent Development
Table 82. Bristol Myers Squibb Company Details
Table 83. Bristol Myers Squibb Business Overview
Table 84. Bristol Myers Squibb CGRP Inhibitor Product
Table 85. Bristol Myers Squibb Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 86. Bristol Myers Squibb Recent Development
Table 87. Satsuma Company Details
Table 88. Satsuma Business Overview
Table 89. Satsuma CGRP Inhibitor Product
Table 90. Satsuma Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 91. Satsuma Recent Development
Table 92. Zosano Pharma Company Details
Table 93. Zosano Pharma Business Overview
Table 94. Zosano Pharma CGRP Inhibitor Product
Table 95. Zosano Pharma Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 96. Zosano Pharma Recent Development
Table 97. Dr.Reddy’s Laboratories Company Details
Table 98. Dr.Reddy’s Laboratories Business Overview
Table 99. Dr.Reddy’s Laboratories CGRP Inhibitor Product
Table 100. Dr.Reddy’s Laboratories Revenue in CGRP Inhibitor Business (2020-2025) & (US$ Million)
Table 101. Dr.Reddy’s Laboratories Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
Table 105. Authors List of This Report
List of Figures
Figure 1. CGRP Inhibitor Picture
Figure 2. Global CGRP Inhibitor Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global CGRP Inhibitor Market Share by Type: 2024 VS 2031
Figure 4. Infusions Features
Figure 5. Oral Features
Figure 6. Other Features
Figure 7. Global CGRP Inhibitor Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global CGRP Inhibitor Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Others Case Studies
Figure 12. CGRP Inhibitor Report Years Considered
Figure 13. Global CGRP Inhibitor Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global CGRP Inhibitor Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global CGRP Inhibitor Market Share by Region: 2024 VS 2031
Figure 16. Global CGRP Inhibitor Market Share by Players in 2024
Figure 17. Global CGRP Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by CGRP Inhibitor Revenue in 2024
Figure 19. North America CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America CGRP Inhibitor Market Share by Country (2020-2031)
Figure 21. United States CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe CGRP Inhibitor Market Share by Country (2020-2031)
Figure 25. Germany CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific CGRP Inhibitor Market Share by Region (2020-2031)
Figure 33. China CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America CGRP Inhibitor Market Share by Country (2020-2031)
Figure 41. Mexico CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa CGRP Inhibitor Market Share by Country (2020-2031)
Figure 45. Turkey CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE CGRP Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. AbbVie Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 49. Amgen Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 50. Eli Lilly Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 51. Teva Pharmaceutical Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 52. Pfizer Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 53. Lundbeck Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 54. Novartis Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 55. Bristol Myers Squibb Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 56. Satsuma Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 57. Zosano Pharma Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 58. Dr.Reddy’s Laboratories Revenue Growth Rate in CGRP Inhibitor Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232